COVID-19 Vaccine Candidate Demonstrates Efficacy Against Variants

Maryland-based Novavax, Inc. announced that its protein-based COVID-19 vaccine candidate NVX-CoV2373 met the primary study endpoint, with a vaccine efficacy of 89.3%, in its Phase 3 clinical trial conducted in the United Kingdom (UK). It was conducted in partnership with the UK Government’s Vaccines Taskforce. 

Furthermore, the study assessed efficacy during a period with high transmission and with a new UK variant strain of the virus emerging and circulating widely.

Novavax also announced successful results of its Phase 2b study in South Africa.

“With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against COVID-19, but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” said Stanley C. Erck, President, and Chief Executive Officer, Novavax, in a press release.

“NVX-CoV2373 has the potential to play an important role in solving this global public health crisis. We look forward to continuing to work with our partners, collaborators, investigators, and regulators around the world to make the vaccine available as quickly as possible," add Erck.